362 related articles for article (PubMed ID: 34044875)
1. A phase 2 double-blind placebo-controlled 24-week treatment clinical study of the p38 alpha kinase inhibitor neflamapimod in mild Alzheimer's disease.
Prins ND; Harrison JE; Chu HM; Blackburn K; Alam JJ; Scheltens P;
Alzheimers Res Ther; 2021 May; 13(1):106. PubMed ID: 34044875
[TBL] [Abstract][Full Text] [Related]
2. Pharmacodynamics of atabecestat (JNJ-54861911), an oral BACE1 inhibitor in patients with early Alzheimer's disease: randomized, double-blind, placebo-controlled study.
Timmers M; Streffer JR; Russu A; Tominaga Y; Shimizu H; Shiraishi A; Tatikola K; Smekens P; Börjesson-Hanson A; Andreasen N; Matias-Guiu J; Baquero M; Boada M; Tesseur I; Tritsmans L; Van Nueten L; Engelborghs S
Alzheimers Res Ther; 2018 Aug; 10(1):85. PubMed ID: 30134967
[TBL] [Abstract][Full Text] [Related]
3. Amyloid positron emission tomography and cerebrospinal fluid results from a crenezumab anti-amyloid-beta antibody double-blind, placebo-controlled, randomized phase II study in mild-to-moderate Alzheimer's disease (BLAZE).
Salloway S; Honigberg LA; Cho W; Ward M; Friesenhahn M; Brunstein F; Quartino A; Clayton D; Mortensen D; Bittner T; Ho C; Rabe C; Schauer SP; Wildsmith KR; Fuji RN; Suliman S; Reiman EM; Chen K; Paul R
Alzheimers Res Ther; 2018 Sep; 10(1):96. PubMed ID: 30231896
[TBL] [Abstract][Full Text] [Related]
4. Neflamapimod: Clinical Phase 2b-Ready Oral Small Molecule Inhibitor of p38α to Reverse Synaptic Dysfunction in Early Alzheimer's Disease.
Alam J; Blackburn K; Patrick D
J Prev Alzheimers Dis; 2017; 4(4):273-278. PubMed ID: 29181493
[TBL] [Abstract][Full Text] [Related]
5. Phase 2A Learnings Incorporated into RewinD-LB, a Phase 2B Clinical Trial of Neflamapimod in Dementia with Lewy Bodies.
Prins ND; de Haan W; Gardner A; Blackburn K; Chu HM; Galvin JE; Alam JJ
J Prev Alzheimers Dis; 2024; 11(3):549-557. PubMed ID: 38706271
[TBL] [Abstract][Full Text] [Related]
6. A randomized, double-blind, phase 2b proof-of-concept clinical trial in early Alzheimer's disease with lecanemab, an anti-Aβ protofibril antibody.
Swanson CJ; Zhang Y; Dhadda S; Wang J; Kaplow J; Lai RYK; Lannfelt L; Bradley H; Rabe M; Koyama A; Reyderman L; Berry DA; Berry S; Gordon R; Kramer LD; Cummings JL
Alzheimers Res Ther; 2021 Apr; 13(1):80. PubMed ID: 33865446
[TBL] [Abstract][Full Text] [Related]
7. Randomized Phase II Study of the Safety and Efficacy of Semorinemab in Participants With Mild-to-Moderate Alzheimer Disease: Lauriet.
Monteiro C; Toth B; Brunstein F; Bobbala A; Datta S; Ceniceros R; Sanabria Bohorquez SM; Anania VG; Wildsmith KR; Schauer SP; Lee J; Dolton MJ; Ramakrishnan V; Abramzon D; Teng E;
Neurology; 2023 Oct; 101(14):e1391-e1401. PubMed ID: 37643887
[TBL] [Abstract][Full Text] [Related]
8. Association of Plasma Phosphorylated Tau With the Response to Neflamapimod Treatment in Patients With Dementia With Lewy Bodies.
Alam JJ; Maruff P; Doctrow SR; Chu HM; Conway J; Gomperts SN; Teunissen C
Neurology; 2023 Oct; 101(17):e1708-e1717. PubMed ID: 37657939
[TBL] [Abstract][Full Text] [Related]
9. Exploratory Tau Biomarker Results From a Multiple Ascending-Dose Study of BIIB080 in Alzheimer Disease: A Randomized Clinical Trial.
Edwards AL; Collins JA; Junge C; Kordasiewicz H; Mignon L; Wu S; Li Y; Lin L; DuBois J; Hutchison RM; Ziogas N; Shulman M; Martarello L; Graham D; Lane R; Budd Haeberlein S; Beaver J
JAMA Neurol; 2023 Dec; 80(12):1344-1352. PubMed ID: 37902726
[TBL] [Abstract][Full Text] [Related]
10. Safety, tolerability and efficacy of the glutaminyl cyclase inhibitor PQ912 in Alzheimer's disease: results of a randomized, double-blind, placebo-controlled phase 2a study.
Scheltens P; Hallikainen M; Grimmer T; Duning T; Gouw AA; Teunissen CE; Wink AM; Maruff P; Harrison J; van Baal CM; Bruins S; Lues I; Prins ND
Alzheimers Res Ther; 2018 Oct; 10(1):107. PubMed ID: 30309389
[TBL] [Abstract][Full Text] [Related]
11. Safety, efficacy, and biomarker findings of PBT2 in targeting Abeta as a modifying therapy for Alzheimer's disease: a phase IIa, double-blind, randomised, placebo-controlled trial.
Lannfelt L; Blennow K; Zetterberg H; Batsman S; Ames D; Harrison J; Masters CL; Targum S; Bush AI; Murdoch R; Wilson J; Ritchie CW;
Lancet Neurol; 2008 Sep; 7(9):779-86. PubMed ID: 18672400
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of tarenflurbil in mild to moderate Alzheimer's disease: a randomised phase II trial.
Wilcock GK; Black SE; Hendrix SB; Zavitz KH; Swabb EA; Laughlin MA;
Lancet Neurol; 2008 Jun; 7(6):483-93. PubMed ID: 18450517
[TBL] [Abstract][Full Text] [Related]
13. Donanemab in Early Symptomatic Alzheimer Disease: The TRAILBLAZER-ALZ 2 Randomized Clinical Trial.
Sims JR; Zimmer JA; Evans CD; Lu M; Ardayfio P; Sparks J; Wessels AM; Shcherbinin S; Wang H; Monkul Nery ES; Collins EC; Solomon P; Salloway S; Apostolova LG; Hansson O; Ritchie C; Brooks DA; Mintun M; Skovronsky DM;
JAMA; 2023 Aug; 330(6):512-527. PubMed ID: 37459141
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of the efficacy, safety and tolerability of orally administered BI 409306, a novel phosphodiesterase type 9 inhibitor, in two randomised controlled phase II studies in patients with prodromal and mild Alzheimer's disease.
Frölich L; Wunderlich G; Thamer C; Roehrle M; Garcia M; Dubois B
Alzheimers Res Ther; 2019 Feb; 11(1):18. PubMed ID: 30755255
[TBL] [Abstract][Full Text] [Related]
15. Plasma neurofilament light and phosphorylated tau 181 as biomarkers of Alzheimer's disease pathology and clinical disease progression.
Clark C; Lewczuk P; Kornhuber J; Richiardi J; Maréchal B; Karikari TK; Blennow K; Zetterberg H; Popp J
Alzheimers Res Ther; 2021 Mar; 13(1):65. PubMed ID: 33766131
[TBL] [Abstract][Full Text] [Related]
16. Randomized Trial of Verubecestat for Prodromal Alzheimer's Disease.
Egan MF; Kost J; Voss T; Mukai Y; Aisen PS; Cummings JL; Tariot PN; Vellas B; van Dyck CH; Boada M; Zhang Y; Li W; Furtek C; Mahoney E; Harper Mozley L; Mo Y; Sur C; Michelson D
N Engl J Med; 2019 Apr; 380(15):1408-1420. PubMed ID: 30970186
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of GV1001 in patients with moderate-to-severe Alzheimer's disease already receiving donepezil: a phase 2 randomized, double-blind, placebo-controlled, multicenter clinical trial.
Koh SH; Kwon HS; Choi SH; Jeong JH; Na HR; Lee CN; Yang Y; Lee AY; Lee JH; Park KW; Han HJ; Kim BC; Park JS; Lee JY; Kim S; Lee KY
Alzheimers Res Ther; 2021 Mar; 13(1):66. PubMed ID: 33771205
[TBL] [Abstract][Full Text] [Related]
18. Clinical Effects of Tramiprosate in APOE4/4 Homozygous Patients with Mild Alzheimer's Disease Suggest Disease Modification Potential.
Abushakra S; Porsteinsson A; Scheltens P; Sadowsky C; Vellas B; Cummings J; Gauthier S; Hey JA; Power A; Wang P; Shen L; Tolar M
J Prev Alzheimers Dis; 2017; 4(3):149-156. PubMed ID: 29182706
[TBL] [Abstract][Full Text] [Related]
19. Tilavonemab in early Alzheimer's disease: results from a phase 2, randomized, double-blind study.
Florian H; Wang D; Arnold SE; Boada M; Guo Q; Jin Z; Zheng H; Fisseha N; Kalluri HV; Rendenbach-Mueller B; Budur K; Gold M
Brain; 2023 Jun; 146(6):2275-2284. PubMed ID: 36730056
[TBL] [Abstract][Full Text] [Related]
20. Effects of Oral ALZ-801/Valiltramiprosate on Plasma Biomarkers, Brain Hippocampal Volume, and Cognition: Results of 2-Year Single-Arm, Open-Label, Phase 2 Trial in APOE4 Carriers with Early Alzheimer's Disease.
Hey JA; Abushakra S; Blennow K; Reiman EM; Hort J; Prins ND; Sheardova K; Kesslak P; Shen L; Zhu X; Albayrak A; Paul J; Schaefer JF; Power A; Tolar M
Drugs; 2024 Jun; ():. PubMed ID: 38902571
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
